newsfilter
← Latest News
GlobeNewswire·

Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for relapsed EGFR ex20ins